Lumida
/PRME
⌘K
Prime Medicine Inc

Prime Medicine Inc

PRME
$3.13USD-6.57%-0.22 today

MARKET CAP

567.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$3
$7

AI Summary

Stalk
Buy NowMedium

PRME is in an Early Stage 1 consolidation range after a prolonged downtrend, with the 9 and 21 EMAs having repaired and turned slightly upward. The Bullish Pivot Point pattern signals failed downside control and structural repair, giving a bullish medium-term mean-reversion bias against a bearish secular trend. Execution favors a Buy Now stance on a pullback into the rising EMA support zone within the base.

  • Q2 revenue beat by 4.4% and EPS beat by 6.3%
  • Net loss narrowed 20% YoY to $42.1M
  • Earnings yield is negative and profitability remains weak
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$3.0M$4.6M
YoY %+55.3%
P / Sales116.1x111.4x
EV / Sales103.3x145.7x
Gross Profit, Adj.$3.0M$4.6M
YoY %+55.3%
Margin %100.0%100.0%
EV / Gross Profit103.3x145.7x
EBITDA, Adj.$-196.3M$-201.0M
YoY %+1.9%-2.4%
Margin %-6581.9%-4340.0%
EV / EBITDA-1.6x-3.4x
EBIT$-202.5M$-208.3M
YoY %+1.1%-2.9%
Margin %-6787.4%-4498.1%
EV / EBIT-1.5x-3.2x
Net Income$-195.9M$-201.1M
YoY %+1.1%-2.7%
Net Margin-6566.6%-4342.4%
EPS (GAAP)-$1.65-$1.35
YoY %+24.3%+18.2%